3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
31
Advanced Solid Tumors
25
Advanced Solid Tumor
24
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
15
Solid Tumor
12
Prostatic Neoplasms
12
Multiple Myeloma
12
Neoplasm Metastasis
11
Recurrence
10
Pancreatic Neoplasms
10
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
9
Lung Neoplasms
9
Stomach Neoplasms
8
Melanoma
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myeloid, Acute
8
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Colorectal Neoplasms
7
Uterine Cervical Neoplasms
6
Solid Tumors
6
Carcinoma, Transitional Cell
5
Advanced Solid Tumour
5
Squamous Cell Carcinoma of Head and Neck
4
Nasopharyngeal Carcinoma
4
Myelodysplastic Syndromes
4
Lymphoma
4
Interventions
pembrolizumab
4
toripalimab
1
efineptakin alfa
1
MK 2206
1
Injections
1
Cetuximab
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Locally Advanced or Metastatic Solid Tumors
×
Injections
×
Clear all
NCT05957471
2023-07-24
BC3195
Biocity Biopharmaceutics Co., Ltd.
Phase 1
Unknown
27 enrolled